Resources from the same session
66O - TACE combined with apatinib in patients with intermediate and advanced hepatocellular carcionma: A prospective, multi-center, randomized clinical trial
Presenter: Bin Liang
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Invited Discussant 66O
Presenter: Teresa Macarulla
Session: Presidential Symposium
Resources:
Slides
Webcast
LBA7 - A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
Presenter: Byoung Chul Cho
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA7
Presenter: Ben Solomon
Session: Presidential Symposium
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Solange Peters
Session: Presidential Symposium
Resources:
Slides
Webcast
LBA8 - Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
Presenter: Tony S.K. Mok
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8
Presenter: Solange Peters
Session: Presidential Symposium
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Solange Peters
Session: Presidential Symposium
Resources:
Slides
Webcast